NDC codes

FDA NDC Directory
Product NDC (as listed)71335-3128Labeler and product segments. Claims need a package NDC.
Product NDC at billing width71335-3128Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
71335-3128-17133531280130 CAPSULE in 1 BOTTLE (71335-3128-1)Marketed from Apr 29, 2026
71335-3128-27133531280290 CAPSULE in 1 BOTTLE (71335-3128-2)Marketed from Apr 29, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Silodosin
Generic name (nonproprietary)
silodosin
Active ingredients
Silodosin — 8 mg/1
Dosage form
Capsule
Route
Oral
Product type
Prescription drug
Marketing category
ANDA — Abbreviated New Drug Application (generic)Application ANDA 211166
Marketing start
Listing expires
Other FDA classes
Adrenergic alpha-Antagonists (Mechanism)
Identifiers
Product ID 71335-3128_88136a96-4e67-477f-8f35-d2b2f99cce08SPL ID 88136a96-4e67-477f-8f35-d2b2f99cce08SPL set ID afbf4823-8663-4152-9346-ca42c7b7d722RxCUI 809477UNII CUZ39LUY82
Pharmacologic class
alpha-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471335312801 followed by a unit qualifier and the quantity

Package 71335-3128-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective .

Indications (excerpt from the label)

Silodosin, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [ see CLINICAL STUDIES ( 14 )]. Silodosin is not indicated for the treatment of hypertension. Silodosin, an alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Silodosin is not indicated for the treatment of hypertension ( 1 ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211166

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211166
ProductStrengthForm · routeLabelerProduct NDC
SilodosinSilodosin 4 mg/1CapsuleOralMacleods Pharmaceuticals Limited33342-384
SilodosinSilodosin 8 mg/1CapsuleOralMacleods Pharmaceuticals Limited33342-385

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in